Drug profile · INN
tecovirimat
TPOXX
tecovirimat (TPOXX) is a envelope phospholipase opg057 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — tecovirimat
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 2
- Data quality
- 0.84
Quick answer
tecovirimat (TPOXX) is a envelope phospholipase opg057 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Envelope phospholipase OPG057 inhibitor
Primary target: Envelope phospholipase OPG057
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is tecovirimat?
tecovirimat (TPOXX) is a envelope phospholipase opg057 inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for tecovirimat?
TPOXX is a marketed brand name for tecovirimat. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of tecovirimat?
tecovirimat has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.